Back

Longitudinal burden of disease in hypertrophic cardiomyopathy: one-year follow-up of the AFFECT-HCM study

30 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: disease burden, risk stratification, and clinical outcomes Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Raveena Mangal

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Real-world clinical burden of obstructive hypertrophic cardiomyopathy: a nationwide study in france
Professor A. Hagege (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Simplified versus complete selvester QRS scoring system for scar assessment in hypertrophic cardiomyopathy patients
Doctor N. Charoenpoonsiri (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Continuous ambulatory ECG monitoring of up to 14 days increases detection of high-risk ventricular tachyarrhythmias compared with the first 48 hours in hypertrophic cardiomyopathy
Doctor M. Maron (Burlington, US)
Abstract Slides Video
Presentation thumbnail
HCM in the modern era: low mortality and predominantly predictable sudden cardiac death under systematic risk stratification
Doctor E. Karvouni (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Mavacamten improves functional status in obstructive hypertrophic cardiomyopathy without increasing serious adverse events: a systematic review and meta-analysis
Doctor I. Figueroa Baez (San Juan, PR)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: disease burden, risk stratification, and clinical outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
AFFECT-HCM: quality of life and costs in hypertrophic cardiomyopathy
31 August 2024
thumbnail
Congress Presentation
Real world safety and efficacy of mavacamten for hypertrophic obstructive cardiomyopathy: the SWISS-MAVA cohort
30 August 2026
thumbnail
Congress Presentation
The influence of genotype on the phenotype and prognosis of patients with hypertrophic cardiomyopathy
19 May 2025
thumbnail
Congress Presentation
Characterizing disease burden and health care resource utilization in patients with hypertrophic cardiomyopathy: a nationwide real-world study in Finland
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources